Silverback Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
Silverback Therapeutics, Inc. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 6 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include IMMUNOTAC, SILVERBACK, and SILVERBACK THERAPEUTICS. The owner is based in Seattle, WA.
500 Fairview Avenue North, Suite 600
Seattle, WA 98109
Showing of trademarks Trademarks
Trademark Classifications
Silverback Therapeutics, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Silverback Therapeutics, Inc. have?
Silverback Therapeutics, Inc. has 7 U.S. trademarks filed with the USPTO. Of these, 4 registered, 3 abandoned.
What trademark classes does Silverback Therapeutics, Inc. file in?
Silverback Therapeutics, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Silverback Therapeutics, Inc.'s most well-known trademarks?
Silverback Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as IMMUNOTAC, SILVERBACK, and SILVERBACK THERAPEUTICS. These are among 4 currently registered trademarks in the portfolio.
What is Silverback Therapeutics, Inc.'s trademark registration success rate?
Silverback Therapeutics, Inc. has a 57% trademark registration rate, with 4 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.